BioCentury on BioBusiness, Emerging Company Profile
Anabasis developing NGF to modify disease in ophthalmic indications
Related tables, figures and sidebars
Anabasis: Eyeing NGF
By Chris Cain
Staff Writer
Published on Monday, January 2, 2012
Anabasis
s.r.l. is developing an ophthalmic formulation of nerve growth factor,
which could become the first disease-modifying treatment for neurotrophic
keratitis, dry eye and glaucoma.
Nerve growth factor (NGF) is a secreted protein that
stimulates the growth and survival of neurons, and has been proposed as a
therapeutic for many neurological diseases. But the most advanced trial of NGF
took place over a decade ago, when an injectable formulation from Genentech
Inc. and Roche failed
a Phase III trial to treat symptoms of diabetic peripheral neuropathy (see
BioCentury, April 12, 1999).
91 words displayed of 738 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]